TRAW
Traws Pharma Inc
NASDAQ: TRAW · HEALTHCARE · BIOTECHNOLOGY
$1.43
+10.00% today
Updated 2026-04-30
Market cap
$11.58M
P/E ratio
1.39
P/S ratio
4.15x
EPS (TTM)
$0.82
Dividend yield
—
52W range
$1 – $3
Volume
0.2M
Traws Pharma Inc (TRAW) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $46.19M | $4.75M | $800000.00 | $11.46M | $5.55M | $787000.00 | $1.23M | $2.18M | $231000.00 | $226000.00 | $226000.00 | $226000.00 | $226000.00 | $2.79M |
| Revenue growth (YoY) | — | +3006.3% | -89.7% | -83.2% | +1332.0% | -51.6% | -85.8% | +56.0% | +77.8% | -89.4% | -2.2% | +0.0% | +0.0% | +0.0% | +1134.5% |
| Cost of revenue | — | $319000.00 | — | — | — | — | — | — | — | — | $14000.00 | $14000.00 | $16000.00 | $12000.00 | $61000.00 |
| Gross profit | $1.49M | $45.87M | $4.75M | $800000.00 | $11.46M | $5.55M | $787000.00 | $1.23M | $2.18M | $231000.00 | $226000.00 | $226000.00 | $226000.00 | $214000.00 | $2.73M |
| Gross margin | 100.0% | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.7% | 97.8% |
| R&D | $22.62M | $52.76M | $49.73M | $49.42M | $25.89M | $20.07M | $19.03M | $16.87M | $15.54M | $16.90M | $7.30M | $11.41M | $11.43M | $130.31M | $12.14B |
| SG&A | $6.44M | $15.71M | $16.79M | $15.12M | $9.53M | — | — | — | $8.35M | $8.33M | $9.43M | $8.45M | $9.09M | $12.29M | $8.52B |
| Operating income | $-27.57M | $-22.28M | $-62.22M | $-63.74M | $-23.97M | $-23.70M | $-25.74M | $-23.28M | $-21.70M | $-24.99M | $-16.50M | $-19.63M | $-20.30M | $-49.35M | $-17.88M |
| Operating margin | -1854.3% | -48.2% | -1309.1% | -7968.0% | -209.3% | -427.4% | -3270.3% | -1895.9% | -994.0% | -10819.5% | -7299.1% | -8684.5% | -8981.4% | -21835.4% | -640.7% |
| EBITDA | $-25.96M | $-20.98M | $-61.67M | $-63.34M | $-23.86M | $-19.56M | $-23.99M | $-20.48M | $-21.68M | $-24.98M | $-16.48M | $-19.61M | $-20.28M | $-166.51M | $-17.81M |
| EBITDA margin | -1745.7% | -45.4% | -1297.5% | -7917.5% | -208.2% | -352.6% | -3048.4% | -1667.7% | -993.4% | -10813.9% | -7292.9% | -8678.3% | -8974.3% | -73677.4% | -638.5% |
| EBIT | $-26.27M | $-21.30M | $-62.11M | $-63.77M | $-24.01M | $-19.65M | $-24.08M | $-20.53M | $-21.70M | $-24.99M | $-16.50M | $-19.63M | $-20.30M | $-166.52M | $-17.88M |
| Interest expense | $19000.00 | $8.61M | $4000.00 | $2000.00 | — | — | — | — | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-30.31M | $-33.87M | $-64.86M | $-63.68M | $-23.98M | $-19.67M | $-24.09M | $-20.57M | $-21.50M | $-25.16M | $-16.16M | $-18.96M | $-18.95M | $-54.67M | $9.17M |
| Net income growth (YoY) | — | -11.7% | -91.5% | +1.8% | +62.3% | +18.0% | -22.5% | +14.6% | -4.5% | -17.0% | +35.8% | -17.3% | +0.1% | -188.5% | +116.8% |
| Profit margin | -2038.6% | -73.3% | -1364.7% | -7960.3% | -209.3% | -354.6% | -3061.2% | -1675.3% | -985.0% | -10890.5% | -7151.8% | -8391.2% | -8384.1% | -24192.0% | 328.7% |